

FIGURE 2B

Potential humanized sequence based on IGKV3-11*01 acceptor framework (AbM CDR definition)
 IGKV3-11*01 EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQKPGQAPRLLIYDASNRA
 GIPARFSGSGGTDFTLTISSLEPEDFAVYVCQQRSNWPP
 Joining region IMGT J00242|IGKJ2*01|YTFGQGTKLEIK

seq	10	20	30	40	50	60
AbM	10	20	30abcd	40	50	50
	b b b	p p	b b b	b b b	i i b b i	i
SB-3F9	DIVLTQSPASLAVSLQQRATISC RASKSVSSSSGYSYMH WYQKPGQPPKLLIY LASNLES					
	*	* * * *	*	*	*	*
3-11*01	EIVLTQSPATLSLSPGERATLSC RASQSVS----SYLA WYQKPGQAPRLLIY DASNRA					
hSB-3F9-L1	EIVLTQSPATLSLSPGERATLSC RASKSVSSSSGYSYMH WYQKPGQAPRLLIY LASNLES					
hSB-3F9-L2	EIVLTQSPATLSLSPGERATLSC RASKSVSSSSGYSYMH WYQKPGQAPRLLIY LASNLES					
hSB-3F9-L3	EIVLTQSPATLSLSPGERATLSC RASKSVSSSSGYSYMH WYQKPGQAPRLLIY LASNLES					

V P #

seq	70	80	90	100	110
AbM	60	70	80	90	100
	b b	b b b	b b b	i b i	b b b
SB-3F9	GVPARFSGSGGTDFTLNIHPVEEEDAATYVC QHNRELPC T FGGGTKLEIK				
	*	* * * *	*	*	*
3-11*01	GIPARFSGSGGTDFTLTISSLEPEDFAVYVC QQRSNWPP				
hSB-3F9-L1	GIPARFSGSGGTDFTLTISSLEPEDFAVYVC QHNRELPC T FGGGTKLEIK				
hSB-3F9-L2	GVPARFSGSGGTDFTLTISSVEPEDFAVYVC QHNRELPC T FGGGTKLEIK				
hSB-3F9-L3	GVPARFSGSGGTDFTLTISSVEPEDFAVYVC QHNRELPC T FGGGTKLEIK				

A # ^

FIGURE 3




FIGURE 4A





FIGURE 4B







FIGURE 5A

FIGURE 5B

FIGURE 6A




FIGURE 6B




FIGURE 7A




FIGURE 7B




FIGURE 8A




FIGURE 8B




FIGURE 9A




FIGURE 9B




FIGURE 10A




FIGURE 10B





FIGURE 11B




FIGURE 11A




FIGURE 12B




FIGURE 12A




FIGURE 13A




FIGURE 13B




FIGURE 14A




FIGURE 14B




FIGURE 15B




FIGURE 15A




FIGURE 16




FIGURE 17A




FIGURE 17B





FIGURE 17C









FIGURE 19A

Group	CD34+ HSC Donor A # mice	CD34+ HSC Donor B # mice	Antibody Treatment	Dose	Schedule	Inoculum
1	2	9	hulG1	10 mpk	q3dx2	3 million A375 cells
2	3	10	3F9-22 PS	10 mpk	q3dx2	3 million A375 cells
3	3	10	3F9-22 NSLF	10 mpk	q3dx2	3 million A375 cells

FIGURE 19B




FIGURE 20A




FIGURE 20B




FIGURE 21A




FIGURE 21B




FIGURE 22




FIGURE 23




FIGURE 24

